Condor Software

About Condor Software

Condor Software offers a financial intelligence and automation platform specifically designed for the biopharma and life sciences industries. Founded in 2020 by Jennifer Kyle and John Yang Sammataro and headquartered in San Diego, CA, the company aims to streamline the financial complexities associated with clinical trials. Jennifer Kyle, the CEO, has a background in building accounting workflows for the pharmaceutical industry, which provided the foundation for Condor's platform. The company was established to address the fragmented processes and disconnected systems that impede medical progress.

The company's business model is centered on providing a software-as-a-service (SaaS) platform to emerging, mid-sized, and enterprise biopharma companies, as well as MedTech firms and contract research organizations (CROs). The platform, known as the Condor Cloud, unifies clinical, operational, and financial data into a single source of truth. It automates and manages processes such as clinical accruals, financial planning, forecasting, vendor management, and audits. This automation helps to accelerate the financial close cycle, improve forecast accuracy, and enhance compliance. By integrating with existing Enterprise Resource Planning (ERP), Clinical Trial Management Systems (CTMS), and other vendor platforms, Condor provides real-time visibility into R&D spending.

The platform includes several key products: 'Copilot' for automating accruals and reconciliations, 'Compass' for forecasting costs and modeling scenarios, and 'Connect' for integrating data across the ecosystem. These tools are designed to provide teams in Accounting, FP&A, and Clinical Operations with the speed, accuracy, and control needed to manage trial finances effectively. Condor reports that its customers, which include Acadia Pharmaceuticals, Alumis Therapeutics, and BridgeBio Pharma, achieve over 90 percent forecast accuracy and a 70 percent faster month-end close. The company has secured significant funding, including a $24 million Series A round in March 2026, bringing its total funding to $36 million with investors like Insight Partners, Felicis, and 645 Ventures.